NCCN Task Force report: Positron emission tomography (PET)/computed tomography (CT) scanning in cancer Journal Article
| Authors: | Podoloff, D. A.; Advani, R. H.; Allred, C.; Benson, A. B. 3rd; Brown, E.; Burstein, H. J.; Carlson, R. W.; Coleman, R. E.; Czuczman, M. S.; Delbeke, D.; Edge, S. B.; Ettinger, D. S.; Grannis, F. W. Jr; Hillner, B. E.; Hoffman, J. M.; Kiel, K.; Komaki, R.; Larson, S. M.; Mankoff, D. A.; Rosenzweig, K. E.; Skibber, J. M.; Yahalom, J.; Yu, J. Q. M.; Zelenetz, A. D. |
| Article Title: | NCCN Task Force report: Positron emission tomography (PET)/computed tomography (CT) scanning in cancer |
| Abstract: | The use of positron emission tomography (PET) is increasing rapidly in the United States, with the most common use of PET scanning related to oncology. It is especially useful in the staging and management of lymphoma, lung cancer, and colorectal cancer, according to a panel of expert radiologists, surgeons, radiation oncologists, nuclear medicine physicians, medical oncologists, and general internists convened in November 2006 by the National Comprehensive Cancer Network. The Task Force was charged with reviewing existing data and developing clinical recommendations for the use of PET scans in the evaluation and management of breast cancer, colon cancer, non-small cell lung cancer, and lymphoma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology. © Journal of the National Comprehensive Cancer Network. |
| Keywords: | clinical trial; review; fluorouracil; treatment; cancer staging; positron emission tomography; cancer diagnosis; neoplasm staging; neoplasm; neoplasms; colorectal cancer; imatinib; computer assisted tomography; controlled clinical trial; breast cancer; lung non small cell cancer; randomized controlled trial; carcinoma, non-small-cell lung; lung cancer; tomography, x-ray computed; practice guideline; pathology; breast neoplasms; oncology; colorectal neoplasms; cost effectiveness analysis; diagnostic agent; drug mechanism; isotope labeling; systematic review; colorectal tumor; breast tumor; diagnosis; lymphoma; fluorodeoxyglucose f 18; medronate technetium tc 99m; fluorodeoxyglucose f18; positron-emission tomography; gefitinib; intermethod comparison; radiography; drug half life; trastuzumab; meta analysis; positron emission tomography (pet); pet/ct; computed tomography (ct); 18f-fdg; carbon 11; gallium; 3' fluorothymidine; rubidium 82; tioxamast; oxygen 15; nitrogen 13; nccn clinical practice guidelines in oncology; humans; prognosis; human; article; standard uptake value |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 5 |
| Issue: | Suppl. 1 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2007-05-01 |
| Start Page: | S-1 |
| End Page: | S-22; quiz S-23-S-24 |
| Language: | English |
| PUBMED: | 17509259 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 22 January 2018 -- Source: Scopus |
